Bio-pharma major Biocon on expansion mode.
Bio-pharma major Biocon is on an expansion mode. The biotech major plans to invest close to Rs 100 crore on its new research and development center located in Bangalore, with a window for future investments going up to Rs 200 crore in next few years.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Biocon stock price
On August 11, 2014, Biocon closed at Rs 459.70, up Rs 0.90, or 0.20 percent. The 52-week high of the share was Rs 553.70 and the 52-week low was Rs 319.00.
The company's trailing 12-month (TTM) EPS was at Rs 15.84 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 29.02. The latest book value of the company is Rs 120.89 per share. At current value, the price-to-book value of the company is 3.80.
Set email alert for
ADS BY GOOGLE
video of the day
Gung-ho over pharma; see BPCL rise 30-40% more: Dimensions